TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Prehabilitation to Enhance Postoperative Functional Capacity Following Esophageal Resection
Brief Summary: Consenting patients scheduled for esophageal resection surgery will be randomized to receive standard nutrition counseling (including nutritional supplements as needed) or standard nutrition counseling and exercise 4 weeks before surgery and 8 weeks after surgery.

It is hypothesized that, compared with the group receiving nutrition alone, the addition of physical exercise to nutrition starting before surgery and continuing for 8 weeks after surgery will have a significantly greater impact on functional walking capacity during the prehabilitation period and during the postoperative period, and on the incidence of postoperative pulmonary complications.


Options:
A: Arm Label: Prehabilitation; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Prehabilitation | Arm Label: No-intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Prehabilitation; Assigned to Arm(s): Prehabilitation
B: Arm Label: Prehabilitation Plus; Type: ACTIVE_COMPARATOR; Interventions: Other: Prehabilitation Plus | Arm Label: Rehabilitation; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Prehabilitation Plus; Assigned to Arm(s): Prehabilitation Plus
C: Arm Label: Exercise; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Exercise | Arm Label: Standard nutrition counselling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Exercise; Assigned to Arm(s): Exercise
D: Arm Label: Prehabilitation group; Type: EXPERIMENTAL; Interventions: Behavioral: Trimodal prehabilitation management | Arm Label: Control group; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Trimodal prehabilitation management; Assigned to Arm(s): Prehabilitation group

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reticulocyte Dynamic and Related Hemoglobin Variability in Hemodialysis Patients Treated With Darbepoetin Alfa and C.E.R.A.: a Randomized Controlled Trial
Brief Summary: Background: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however lessened by the variability induced by more frequent dosage adjustments. The purpose of this study was to analyze the reticulocyte and hemoglobin kinetics under different ESAs and administration intervals in a collective of chronic hemodialysis patients.

Methods: The study was designed as an open-label, randomized, four-period cross-over investigation, including 30 patients under chronic hemodialysis at the regional hospital of Locarno (Switzerland) in September 2009 and lasting 2 years. Four treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin alfa Q4W and Q2W) were compared with each other. The mean square successive difference of hemoglobin, reticulocyte count and ESAs dose was used to quantify variability. We distinguished a short- and a long-term variability based respectively on the weekly and monthly successive difference.


Options:
A: Arm Label: C.E.R.A.; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Arm Label: Darbepoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Intervention Type: DRUG; Name: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals; Assigned to Arm(s): C.E.R.A., Darbepoetin
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: methoxy polyethylene glycol-epoetin beta [Mircera] | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin | Intervention Type: DRUG; Name: epoetin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: methoxy polyethylene glycol-epoetin beta [Mircera]; Assigned to Arm(s): 1
C: Arm Label: Methoxy Polyethylene Glycol-epoetin Beta; Type: EXPERIMENTAL; Interventions: Drug: Methoxy Polyethylene Glycol-epoetin Beta | Arm Label: Epoetin Beta or Darbepoetin Alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Beta, Drug: Darbepoetin Alfa | Intervention Type: DRUG; Name: Methoxy Polyethylene Glycol-epoetin Beta; Assigned to Arm(s): Methoxy Polyethylene Glycol-epoetin Beta | Intervention Type: DRUG; Name: Epoetin Beta; Assigned to Arm(s): Epoetin Beta or Darbepoetin Alfa | Intervention Type: DRUG; Name: Darbepoetin Alfa; Assigned to Arm(s): Epoetin Beta or Darbepoetin Alfa
D: Arm Label: Mircera in Renal Anemia; Type: EXPERIMENTAL; Interventions: Drug: Methoxy polyethylene glycol-epoetin beta | Intervention Type: DRUG; Name: Methoxy polyethylene glycol-epoetin beta; Assigned to Arm(s): Mircera in Renal Anemia

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Reticulocyte Dynamic and Related Hemoglobin Variability in Hemodialysis Patients Treated With Darbepoetin Alfa and C.E.R.A.: a Randomized Controlled Trial
Brief Summary: Background: In a simulation based on a pharmacokinetic model we demonstrated that increasing the erythropoiesis stimulating agents (ESAs) half-life or shortening their administration interval decreases hemoglobin variability. The benefit of reducing the administration interval was however lessened by the variability induced by more frequent dosage adjustments. The purpose of this study was to analyze the reticulocyte and hemoglobin kinetics under different ESAs and administration intervals in a collective of chronic hemodialysis patients.

Methods: The study was designed as an open-label, randomized, four-period cross-over investigation, including 30 patients under chronic hemodialysis at the regional hospital of Locarno (Switzerland) in September 2009 and lasting 2 years. Four treatment strategies (C.E.R.A. every 4 weeks Q4W and every 2 weeks Q2W, Darbepoetin alfa Q4W and Q2W) were compared with each other. The mean square successive difference of hemoglobin, reticulocyte count and ESAs dose was used to quantify variability. We distinguished a short- and a long-term variability based respectively on the weekly and monthly successive difference.


Options:
A: Arm Label: Early Epoetin Beta Therapy; Type: EXPERIMENTAL; Interventions: Drug: epoetin beta [NeoRecormon] | Arm Label: Late Epoetin Beta Therapy; Type: ACTIVE_COMPARATOR; Interventions: Drug: epoetin beta [NeoRecormon] | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Early Epoetin Beta Therapy | Intervention Type: DRUG; Name: epoetin beta [NeoRecormon]; Assigned to Arm(s): Late Epoetin Beta Therapy
B: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin alfa or Epoetin beta | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin alfa or Epoetin beta; Assigned to Arm(s): Epoetin
C: Arm Label: Peginesatide; Type: EXPERIMENTAL; Interventions: Drug: peginesatide | Arm Label: Epoetin alfa; Type: ACTIVE_COMPARATOR; Interventions: Drug: Epoetin Alfa | Intervention Type: DRUG; Name: peginesatide; Assigned to Arm(s): Peginesatide | Intervention Type: DRUG; Name: Epoetin Alfa; Assigned to Arm(s): Epoetin alfa
D: Arm Label: C.E.R.A.; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Arm Label: Darbepoetin; Type: ACTIVE_COMPARATOR; Interventions: Drug: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals | Intervention Type: DRUG; Name: comparison between darbepoetin alfa and C.E.R.A. and different administration intervals; Assigned to Arm(s): C.E.R.A., Darbepoetin

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Vaccine Hesitancy Intervention--Provider (VHIP)
Brief Summary: The primary aim of this trial is to test the effectiveness of an intervention to train primary care physicians to determine if it leads to decreased parental vaccine hesitancy.


Options:
A: Arm Label: Intervention Clinics; Type: EXPERIMENTAL; Interventions: Behavioral: Academic Detailing | Arm Label: Control Clinics; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Academic Detailing; Assigned to Arm(s): Intervention Clinics
B: Arm Label: Participatory; Type: EXPERIMENTAL; Interventions: Behavioral: Participatory | Arm Label: Efficient; Type: EXPERIMENTAL; Interventions: Behavioral: Efficient | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Participatory; Assigned to Arm(s): Participatory | Intervention Type: BEHAVIORAL; Name: Efficient; Assigned to Arm(s): Efficient
C: Arm Label: P3 Vaccine Promotion Package; Type: EXPERIMENTAL; Interventions: Behavioral: P3 Vaccine Promotion Package. | Arm Label: No P3 vaccine promotion package intervention; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: P3 Vaccine Promotion Package.; Assigned to Arm(s): P3 Vaccine Promotion Package
D: Arm Label: Group A; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Group B; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization | Arm Label: Group C; Type: EXPERIMENTAL; Interventions: Behavioral: Enhanced Community mobilization, Biological: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA | Intervention Type: BEHAVIORAL; Name: Enhanced Community mobilization; Assigned to Arm(s): Group B, Group C | Intervention Type: BIOLOGICAL; Name: Combined Oral Polio Vaccine and Inject able Polio Vaccine during SIA; Assigned to Arm(s): Group C

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sensitive Periods in Human Flavor Learning
Brief Summary: The goals of the proposed research are to specify the timing and consequences of the sensitive period for flavor learning in infants who are being breastfed or formula fed. The investigators will conduct a randomized within- and between-subject study of women and their infants during a 15-month window.


Options:
A: Arm Label: Standard well child care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Food Activity Breast feeding support; Type: EXPERIMENTAL; Interventions: Behavioral: FAB | Arm Label: Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: Sleep | Arm Label: FAB + Sleep; Type: EXPERIMENTAL; Interventions: Behavioral: FAB, Behavioral: Sleep | Intervention Type: BEHAVIORAL; Name: FAB; Assigned to Arm(s): FAB + Sleep, Food Activity Breast feeding support | Intervention Type: BEHAVIORAL; Name: Sleep; Assigned to Arm(s): FAB + Sleep, Sleep
B: Arm Label: Active Control Arm; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Injury Prevention Arm | Arm Label: Health Communication and Obesity Prevention; Type: EXPERIMENTAL; Interventions: Behavioral: Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Health Communication and Obesity Prevention; Assigned to Arm(s): Health Communication and Obesity Prevention | Intervention Type: BEHAVIORAL; Name: Injury Prevention Arm; Assigned to Arm(s): Active Control Arm
C: Arm Label: 1M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 1M1.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 3M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Timing of Diet and Flavor Experience; Assigned to Arm(s): 1M0.5, 1M1.5, 3M0.5
D: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control | Arm Label: Email and 4 Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Emails and 4 Home Visits | Arm Label: Email and 2 Home Visits; Type: EXPERIMENTAL; Interventions: Behavioral: Emails and 2 home visits | Intervention Type: BEHAVIORAL; Name: Emails and 4 Home Visits; Assigned to Arm(s): Email and 4 Home Visits | Intervention Type: BEHAVIORAL; Name: Control; Assigned to Arm(s): Control | Intervention Type: BEHAVIORAL; Name: Emails and 2 home visits; Assigned to Arm(s): Email and 2 Home Visits

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sensitive Periods in Human Flavor Learning
Brief Summary: The goals of the proposed research are to specify the timing and consequences of the sensitive period for flavor learning in infants who are being breastfed or formula fed. The investigators will conduct a randomized within- and between-subject study of women and their infants during a 15-month window.


Options:
A: Arm Label: Immediate Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating and Physical Activity | Arm Label: Delayed Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Eating and Physical Activity | Intervention Type: BEHAVIORAL; Name: Healthy Eating and Physical Activity; Assigned to Arm(s): Delayed Intervention, Immediate Intervention
B: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Healthy Food and Physical Activity Environments | Arm Label: Comparison; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Comparison Group | Intervention Type: BEHAVIORAL; Name: Healthy Food and Physical Activity Environments; Assigned to Arm(s): Intervention | Intervention Type: BEHAVIORAL; Name: Comparison Group; Assigned to Arm(s): Comparison
C: Arm Label: 1M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 1M1.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 3M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Timing of Diet and Flavor Experience; Assigned to Arm(s): 1M0.5, 1M1.5, 3M0.5
D: Arm Label: intervention 1; Type: EXPERIMENTAL; Interventions: Behavioral: classroom curriculum, Behavioral: In-service training for Head Start teachers/aides, Behavioral: Training for Head Start food service, Behavioral: Family intervention component, Behavioral: Food source, Behavioral: Health care providers, Behavioral: CHILE Head Start Intervention | Arm Label: control 2; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: classroom curriculum; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: In-service training for Head Start teachers/aides; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Training for Head Start food service; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Family intervention component; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Food source; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: Health care providers; Assigned to Arm(s): intervention 1 | Intervention Type: BEHAVIORAL; Name: CHILE Head Start Intervention; Assigned to Arm(s): intervention 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Sensitive Periods in Human Flavor Learning
Brief Summary: The goals of the proposed research are to specify the timing and consequences of the sensitive period for flavor learning in infants who are being breastfed or formula fed. The investigators will conduct a randomized within- and between-subject study of women and their infants during a 15-month window.


Options:
A: Arm Label: Healthy Lifestyles Group; Type: EXPERIMENTAL; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Arm Label: Healthy Business Group; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Keys to Healthy Family Child Care Homes | Intervention Type: BEHAVIORAL; Name: Keys to Healthy Family Child Care Homes; Assigned to Arm(s): Healthy Business Group, Healthy Lifestyles Group
B: Arm Label: No food; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Plumpy Doz; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Plumpy Doz | Arm Label: Wheat Soy Blend (WSB++); Type: EXPERIMENTAL; Interventions: Dietary Supplement: Wheat Soy Blend (WSB++) | Arm Label: Chickpea based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Chickpea based complementary food supplement | Arm Label: Rice based complementary food supplement; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Wheat Soy Blend (WSB++); Assigned to Arm(s): Wheat Soy Blend (WSB++) | Intervention Type: DIETARY_SUPPLEMENT; Name: Chickpea based complementary food supplement; Assigned to Arm(s): Chickpea based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Rice based complementary food supplement; Assigned to Arm(s): Rice based complementary food supplement | Intervention Type: DIETARY_SUPPLEMENT; Name: Plumpy Doz; Assigned to Arm(s): Plumpy Doz
C: Arm Label: Control; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Self monitoring | Arm Label: Daily reward; Type: EXPERIMENTAL; Interventions: Behavioral: Monetary incentives, Behavioral: Self monitoring | Arm Label: Delayed reward; Type: EXPERIMENTAL; Interventions: Behavioral: Monetary incentives, Behavioral: Self monitoring | Intervention Type: BEHAVIORAL; Name: Monetary incentives; Assigned to Arm(s): Daily reward, Delayed reward | Intervention Type: BEHAVIORAL; Name: Self monitoring; Assigned to Arm(s): Control, Daily reward, Delayed reward
D: Arm Label: 1M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 1M1.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: 3M0.5; Type: EXPERIMENTAL; Interventions: Other: Timing of Diet and Flavor Experience | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Timing of Diet and Flavor Experience; Assigned to Arm(s): 1M0.5, 1M1.5, 3M0.5

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family-Based Juvenile Drug Court Services
Brief Summary: The objective of the proposed study is to adapt and implement an efficacious adolescent substance abuse treatment, Multidimensional Family Therapy (MDFT), within the juvenile drug court service system. Additionally, the investigators will also examine the extent to which MDFT can enhance the effectiveness of existing juvenile drug court services in terms of decreasing drug use, delinquent behavior and arrests and improving school and vocational outcomes. The study design is a fully randomized controlled trial.


Options:
A: Arm Label: Motivational Interviewing; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Interviewing | Arm Label: Supervision As Usual; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Motivational Computer; Type: EXPERIMENTAL; Interventions: Behavioral: Motivational Computer | Intervention Type: BEHAVIORAL; Name: Motivational Interviewing; Assigned to Arm(s): Motivational Interviewing | Intervention Type: BEHAVIORAL; Name: Motivational Computer; Assigned to Arm(s): Motivational Computer
B: Arm Label: Miami Juvenile Drug Court-MDFT; Type: EXPERIMENTAL; Interventions: Behavioral: Miami Juvenile Drug Court-MDFT | Arm Label: Miami Juvenile Drug Court -TAU; Type: OTHER; Interventions: Behavioral: Miami Juvenile Drug Court -TAU | Intervention Type: BEHAVIORAL; Name: Miami Juvenile Drug Court-MDFT; Assigned to Arm(s): Miami Juvenile Drug Court-MDFT | Intervention Type: BEHAVIORAL; Name: Miami Juvenile Drug Court -TAU; Assigned to Arm(s): Miami Juvenile Drug Court -TAU
C: Arm Label: Patient Noncompliance; Type: EXPERIMENTAL; Interventions: Drug: haloperidol decanoate, Drug: haloperidol, Behavioral: Customized Adherence Enhancement | Intervention Type: DRUG; Name: haloperidol decanoate; Assigned to Arm(s): Patient Noncompliance | Intervention Type: DRUG; Name: haloperidol; Assigned to Arm(s): Patient Noncompliance | Intervention Type: BEHAVIORAL; Name: Customized Adherence Enhancement; Assigned to Arm(s): Patient Noncompliance
D: Arm Label: Extended-release naltrexone (XR-NTX); Type: ACTIVE_COMPARATOR; Interventions: Drug: Extended-Release Naltrexone | Arm Label: Motivational Enhancement Counseling Only; Type: PLACEBO_COMPARATOR; Interventions: Behavioral: Motivational Enhancement Counseling | Intervention Type: DRUG; Name: Extended-Release Naltrexone; Assigned to Arm(s): Extended-release naltrexone (XR-NTX) | Intervention Type: BEHAVIORAL; Name: Motivational Enhancement Counseling; Assigned to Arm(s): Motivational Enhancement Counseling Only

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Family-Based Juvenile Drug Court Services
Brief Summary: The objective of the proposed study is to adapt and implement an efficacious adolescent substance abuse treatment, Multidimensional Family Therapy (MDFT), within the juvenile drug court service system. Additionally, the investigators will also examine the extent to which MDFT can enhance the effectiveness of existing juvenile drug court services in terms of decreasing drug use, delinquent behavior and arrests and improving school and vocational outcomes. The study design is a fully randomized controlled trial.


Options:
A: Intervention Type: BIOLOGICAL; Name: MN rgp120/HIV-1 and A244 rgp120/HIV-1; Assigned to Arm(s): N/A
B: Arm Label: Miami Juvenile Drug Court-MDFT; Type: EXPERIMENTAL; Interventions: Behavioral: Miami Juvenile Drug Court-MDFT | Arm Label: Miami Juvenile Drug Court -TAU; Type: OTHER; Interventions: Behavioral: Miami Juvenile Drug Court -TAU | Intervention Type: BEHAVIORAL; Name: Miami Juvenile Drug Court-MDFT; Assigned to Arm(s): Miami Juvenile Drug Court-MDFT | Intervention Type: BEHAVIORAL; Name: Miami Juvenile Drug Court -TAU; Assigned to Arm(s): Miami Juvenile Drug Court -TAU
C: Arm Label: Methadone plus Patient Navigation; Type: EXPERIMENTAL; Interventions: Drug: Methadone, Behavioral: Patient Navigation | Arm Label: Methadone; Type: EXPERIMENTAL; Interventions: Drug: Methadone | Arm Label: Enhanced Treatment as Usual; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Enhanced Treatment as Usual (ETAU) | Intervention Type: DRUG; Name: Methadone; Assigned to Arm(s): Methadone, Methadone plus Patient Navigation | Intervention Type: BEHAVIORAL; Name: Patient Navigation; Assigned to Arm(s): Methadone plus Patient Navigation | Intervention Type: BEHAVIORAL; Name: Enhanced Treatment as Usual (ETAU); Assigned to Arm(s): Enhanced Treatment as Usual
D: Arm Label: Recovery management intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Recovery management | Intervention Type: BEHAVIORAL; Name: Recovery management; Assigned to Arm(s): Recovery management intervention

Answer: B